IMMUNEONCO-B (01541) announced that the first patient has been dosed in a Phase III clinical trial evaluating IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma. IMM0306, independently developed by the group, is a bispecific molecule targeting both cluster of differentiation 47 (CD47) and cluster of differentiation 20 (CD20). It is the world's first CD47 and CD20 dual-targeting bispecific molecule to enter clinical development. IMM0306 works by blocking the "don't eat me" signal through inhibition of CD47-SIRPα interaction, while enhancing Fc-FcɣRIIa and Fc-FcɣRIIIa interactions to activate macrophages and natural killer cells. The molecule preferentially binds to CD20 over CD47, enabling effective elimination of malignant B cells with minimized toxicity, thereby potentially improving therapeutic outcomes. As of the announcement date, the group holds global intellectual property and commercialization rights for IMM0306.